Ken Miyaguchi, PhD, received his doctorate in medical science from the Tokyo Medical and Dental University, Japan, in 2012. He worked as a specially appointed assistant professor, investigating breast cancer until 2015. As a postdoctoral associate at Weill Medical College of Cornell University, New York, Miyaguchi studied a novel brain tumor model generated from hESC-derived cerebral organoid with patient-derived glioma stem cells. He joined the Yu Laboratory as a project scientist in 2018. Miyaguchi’s current focus is on translating basic cancer research and immunotherapy targeting glioma stem cells into effective therapies for patients with brain tumors.
Bong Seop Lee, PhD, is a research scientist at Cedars-Sinai's Department of Neurosurgery. His research areas include design and development of nanometer-sized drug/prodrug and drug delivery systems; targeted cancer therapy using nanodrugs/nanoprodrugs; targeted cancer immunotherapy using B7-H1 inhibitory nanoprodrugs; targeted treatment of Alzheimer's disease using anti-inflammatory nanoprodrugs; and development of imaging and diagnostic agents using nanoparticles. His recent research is focused on targeted therapies for brain tumors, breast cancer, and pancreatic cancer using oxidative stimuli-sensitive camptothecin nanoprodrug and anti-immunosuppressive nanoprodrugs that are able to pass through the blood-brain barrier and selectively accumulate in tumor tissues. Lee earned his bachelor's and master's degrees in chemistry from the University of Technology in Darmstadt, Germany. He earned his doctorate in biochemistry from the University of Regensburg, Germany.
Lei Zhang, MD, PhD, is a project scientist at Cedars-Sinai's Department of Neurosurgery. His research focuses on glioma stem cells and dendritic immunotherapy. He is planning to apply stem cell specific cytotoxic T lymphocytes to target glioma stem cells to prevent the recurrence of malignant glioma. Zhang earned his bachelor's degree from China Medical University and his PhD from the University of Yamanashi, Japan. He received his postdoctoral training at the University of Calgary, Canada, and Mayo Clinic, Rochester.
Hongqiang Wang, MD, is currently a research associate III at Cedars-Sinai's Department of Neurosurgery and works as a clinical trial team member. His main research area is manufacturing vaccines for brain tumor patients and monitoring their immune responses to assess the efficacy of vaccines for the treatment of brain tumor. Wang earned his MD at Shanghai Medical University (now Shanghai Medical School of Fudan University) and joined Cedars-Sinai in 2008.
Sung June Lee received his bachelor's degree in integrative biology from the University of California, Berkeley. His main interests are investigating a novel pathway to target therapeutic biomarkers for glioblastoma cells and enhancing the activity of tumor-infiltrating T-cells.
Minzhi (Maggie) Liu is a research associate at Cedars-Sinai's Department of Neurosurgery. Her research uses cell and molecular biology techniques to work with a gene therapy research project. Liu earned her bachelor's degree at Jinan University, Medical School, China. She worked and trained at Johns Hopkins Hospital for over 10 years before joining Yu Laboratory.